Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529230 · ClinicalTrials.gov registry record
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 46
- Enrollment target
NCT00529230: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT00529230 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00529230 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 46 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To determine the prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes. Secondary Objective: 1\. To determine the degree of sexual dysfunction, fatigue, and depression prevalent in male patients on chronic opioid therapy for cancer-related pain syndromes.
Interventions
- BEHAVIORAL Questionnaire
- OTHER Blood draws to assess gonadal function
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2001-12-11 |
| Est. Completion | 2004-02-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529230
The ClinicalTrials.gov registry entry for NCT00529230 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire is the first listed.
NCT00529230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529230 about?
NCT00529230 is a clinical study titled "Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes". Primary Objective: 1\. To determine the prevalence of secondary hypogonadism in male patients on chronic opioid therapy for cancer-related pain syndromes. Secondary Objective: 1\. To determine the degree of sexual dysfunction, fatigue, and depression prevalent in male patients on chronic opioid t...
What is the current status of trial NCT00529230?
This trial is currently terminated. The enrollment target is 46 participants. The study started on 2001-12-11. Estimated completion is 2004-02-19.
What interventions are being tested in trial NCT00529230?
The interventions under investigation include: Questionnaire (BEHAVIORAL), Blood draws to assess gonadal function (OTHER).
Who is sponsoring clinical trial NCT00529230?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.